Sec Form 13G Filing - SB INVESTMENT ADVISERS (UK) LTD @ 10x Genomics Inc.

Sec Form 13G Filing - SB INVESTMENT ADVISERS (UK) LTD filing for 10x Genomics Inc. (TXG) - 2021-02-16

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Link

United States

Securities and Exchange Commission

Washington, D.C. 20549

Schedule 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

10x Genomics, Inc.

(Name of Issuer)

Class A Common Stock, $0.00001 par value

(Title of Class of Securities)

88025U109

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐	Rule 13d-1(b)

☐	Rule 13d-1(c)

☒	Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 88025U109		Schedule 13G		Page 1 of 7


CUSIP No. 88025U109		Schedule 13G		Page 2 of 7


CUSIP No. 88025U109		Schedule 13G		Page 3 of 7

ITEM 1. (a) Name of Issuer:

10x Genomics, Inc. (the “Issuer”)

(b)

Address of Issuer’s Principal Executive Offices:

6230 Stoneridge Mall Road

Pleasanton, California 94588

ITEM 2. (a) Name of Person Filing:

Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

SoftBank Vision Fund (AIV M2) L.P.

SB Investment Advisers (UK) Limited

(b)

Address or Principal Business Office:

The principal business address for SoftBank Vision Fund (AIV M2) L.P. is 251 Little Falls Drive, Wilmington, DE 19808. The principal business address for SB Investment Advisers (UK) Limited is 69 Grosvenor Street, London W1K 3JP, United Kingdom.

(c)

Citizenship of each Reporting Person is:

SoftBank Vision Fund (AIV M2) L.P. is organized under the laws of the state of Delaware. SB Investment Advisers (UK) Limited is organized under the laws of England and Wales.

(d)

Title of Class of Securities:

Class A common stock, $0.00001 par value per share (the “Class A Common Stock”).

(e)

CUSIP Number:

88025U109

ITEM 3.

Not applicable.

ITEM 4. Ownership.

(a-c)


CUSIP No. 88025U109		Schedule 13G		Page 4 of 7

This amendment to Schedule 13G is being filed on behalf of the Reporting Persons to report that, as of the date hereof, the Reporting Persons do not beneficially own any shares of Class A Common Stock.


Reporting Person	Amount beneficially owned		Percent of class:			Sole power to vote or to direct the vote:		Shared power to vote or to direct the vote:		Sole power to dispose or to direct the disposition of:		Shared power to dispose or to direct the disposition of:
SoftBank Vision Fund (AIV M2) L.P.		0		0	%		0		0		0		0
SB Investment Advisers (UK) Limited		0		0	%		0		0		0		0

SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager (“AIFM”) and is exclusively responsible for managing SoftBank Vision Fund (AIV M2) L.P. in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SoftBank Vision Fund (AIV M2) L.P., SB Investment Advisers (UK) Limited is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund (AIV M2) L.P.’s investments.

ITEM 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

ITEM 6.

Ownership of More Than Five Percent on Behalf of Another Person.

Not applicable.

ITEM 7.

Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

ITEM 8.

Identification and Classification of Members of the Group.

Not applicable.

ITEM 9.

Notice of Dissolution of Group.

Not applicable.


CUSIP No. 88025U109		Schedule 13G		Page 5 of 7

ITEM 10.

Certification.

Not applicable.


CUSIP No. 88025U109		Schedule 13G		Page 6 of 7

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 16, 2021


SoftBank Vision Fund (AIV M2) L.P.
By: SB Investment Advisers (UK) Limited, its Manager

By:		/s/ Brian Wheeler
Name:		Brian Wheeler
Title:		General Counsel

SB Investment Advisers (UK) Limited

By:		/s/ Brian Wheeler
Name:		Brian Wheeler
Title:		General Counsel


CUSIP No. 88025U109		Schedule 13G		Page 7 of 7

LIST OF EXHIBITS


Exhibit No.		Description
99		Joint Filing Agreement (incorporated by reference to the Schedule 13G filed by the Reporting Persons on February 14, 2020).

Names of Reporting Persons

SoftBank Vision Fund (AIV M2) L.P.

Check the Appropriate Box if a Member of a Group

(a) ☐ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Delaware